Symbol not found

NASDAQ:JAGX   00:00AM GMT
0.00
0.00 (0.00%)
Products

Jaguar Health Enters Exclusive Crofelemer License, Commercialization Agreement With Synworld Technologies For Canalevia

Published: 06/29/2022 12:45 GMT
Jaguar Health Inc (JAGX) - Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement With Synworld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China.
Jaguar Health Inc - License Fees of $5.0 Million, and Up to $5.0 Million in Unregistered Equity Infusion, Over Next 24 Months.
Jaguar Health - Service Agreement of Up to $5.0 Million Payable in Unregistered Jaguar Stock to Synworld to Support Approval of Crofelemer in China.